Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News St Jude Medical’s Portico Heart Valves perform well in new trial

St Jude Medical’s Portico Heart Valves perform well in new trial

30th October 2013

St Jude Medical has announced encouraging findings from the Portico Transfemoral CE Mark Trial, a new study of its Portico Transcatheter Aortic Heart Valves.

According to preliminary data from the trial, the Portico 23 and 25 mm valves has been shown to provide a significant improvement in valve function at 30 days among patients diagnosed with severe aortic stenosis.

The devices were also revealed to deliver exceptional haemodynamic performance and improvement in the severity of heart failure symptoms, with additional study results reinforcing the safety and efficacy of the valves beyond 30 days among patients that have completed longer-term follow up.

Frank Callaghan, president of the St Jude Medical cardiovascular and ablation technologies division, said: "St Jude Medical has a long history of developing world-class heart valve technologies. Today's positive results speak to our capability and commitment to bring meaningful advancements to patients with heart valve disease."

The Portico 23 mm valve received European CE Mark approval in November 2012, with a review process still ongoing for the 25 mm version.

St Jude Medical is also seeking US regulatory approval for the device.ADNFCR-8000103-ID-801655120-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.